Researchers report the addition of an FDA approved chemotherapy drug called hydroxyyurea to temozolomide helps to increase survival rates in animal models of glioblastoma.
A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.
Arsenic trioxide, a treatment used for acute promyelocytic leukemia, may help extend lifespan in patients with glioblastoma brain cancer, a new study reports.
Researchers have identified a biomarker that can help predict a patient's prognosis and response to therapies for glioblastoma brain cancer subtypes.
UCLA researchers report erlotinib, an FDA approved drug, reduces glucose uptake in glioblastoma, effectively cutting off nutrients and energy supply to the tumor.
A new study reports researchers have identified a mechanism that aids the growth of glioblastoma brain cancer. By blocking the mechanism, researchers were able to halt the progression of the tumors.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
Researchers discover a mechanism that may underpin the progression of glioblastoma brain cancer development.
Researchers have developed a new drug that could help prolong the lives of people with glioblastoma brain cancer.